Replies to post #11420 on StocksDiva Bio Bin

[StocksDiva]

BIND Therapeutics barasertib data positive, says JMP Securities
JMP Securities notes that pre-clinical studies of BIND's barasertib showed enhanced anti-tumor activity and reduced bone marrow toxicity. The firm thinks the company could overcome the need for lengthy drug infusion and high rates of febrile neutropenia, shown in a previous studiy, by extending the half-life of the drug. The firm reiterates a $30 price target and Outperform rating on the stock.
http://www.theflyonthewall.com/permalinks/entry.php/BINDid1992466/BIND-BIND-Therapeutics-barasertib-data-positive--says-JMP-Securities